Walt Addison Linscott, Chief Business Officer at Indaptus Therapeutics, Inc. (INDP), bought 150 shares at $2.62 ($393) on 2022-09-07, disclosed to the SEC on 2022-09-09.
Open-market purchase of $393 INDP by Chief Business Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.